Selective blockade of IL-23p19 with BI 655066 is associated with significant improvement in QoL outcomes compared with ustekinumab in patients with moderate-to-severe plaque psoriasis

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2016)

引用 0|浏览14
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要